D. E. Shaw & Co., Inc. Gamida Cell Ltd. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $74,956 - $243,351	102,680 Added 459.62%	125,020 $241,000
Q1 2023 May 15, 2023	BUY	$0.68 - $1.71 $15,191 - $38,201	22,340 New	22,340 $18,000
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.39 $108,828 - $241,130	-71,130 Reduced 77.72%	20,391 $32,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $85,332 - $211,604	-49,325 Reduced 35.02%	91,521 $162,000
Q1 2022 May 16, 2022	SELL	$2.22 - $4.47 $250,702 - $504,792	-112,929 Reduced 44.5%	140,846 $585,000

Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $399,504 - $809,904	-181,593 Reduced 41.71%	253,775 $644,000
Q3 2021 Nov 15, 2021	BUY	$3.85 - $6.44 $1.14 Million - $1.91 Million	295,928 Added 212.23%	435,368 $1.71 Million
Q2 2021 Aug 16, 2021	BUY	$5.85 - $8.33 $815,724 - $1.16 Million	139,440 New	139,440 $894,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.